* If you want to update the article please login/register
The PROACT trial will determine the effectiveness of the ACE inhibitor enalapril maleate in preventing cardiotoxicity in breast cancer and non-Hodgkin's lymphoma patients receiving anthracycline-based chemotherapy. Methods and evaluation PROACT is a prospective, randomised, open-label, blinded end-point trial that will enroll adult patients being treated for breast cancer and NHL at NHS hospitals around England. The trial aims to select 106 participants, who will be randomly assigned to standard care plus enalapril or standard care alone based on standards care. Patients randomized to the intervention arm will be given enalapril enalapril, starting chemotherapy and ending with 3 weeks after the last anthracycline dose. The most notable result is the presence or absence of cardiac troponin T release at any time during anthracycline therapy, and 1 month after the last dose of anthracycline.
Source link: https://europepmc.org/article/MED/36585130
It was also aimed to identify predictive biomarkers in the current study, which was also designed to prospectively determine the incidence and associated risk factors of FPu2011induced cardiotoxicity in CRC patients and then identify predictive biomarkers. During FP chemotherapy, a total of 129 consecutive untreated CRC patients underwent intensive cardiology monitoring, including 5u2011items simplified questionnaire on symptoms, electrocardiogram, and plasma sample collection during FP chemotherapy. The correlation of FIC with well-known cardiovascular risk factors and the finding of circulating biomarkers as predictors of FIC was among secondary objectives. Dypnoea and chest pain were the most common signs, but only 15% of patients had ECG abnormalities, including one acute myocardial infarction. In 90% of patients with a positive result, a favourable result was attempted with FP. Only the subgroup of females with a high risk of FIC showed an elevated risk of FIC. FIC can be unexpected, life-threatening adverse event that can restrict the subsequent treatment choices in patients with CRC.
Source link: https://europepmc.org/article/MED/36562382
The leading cause of breast cancer survivors is cardiovascular disease. Anthracyclines and trastuzumab have been linked to an elevated risk of cardiovascular disease, prompting the need for a close follow-up when signs of clinical heart arrest or asymptomatic left ventricular systolic dysfunction have been identified. At our medical center from January 2014 to December 2021, we followed 459 women who were diagnosed with breast cancer from January 2014 to December 2021 and analyzed baseline characteristics, oncologic treatment, and results. Patients who were exposed to neurohormonal antagonists were more likely to have hypertension, hyperlipidemia, and diabetes. Patients who were older, smokers within the last ten years, or who received a combination of both trastuzumab and anthracycline therapy were at a higher risk of cardiotoxicity. In conclusion, previous use of ACE-I/ARBs and u03b2-blockers, alone or in combination, did not result in a decrease in the development of cardiovascular disease in patients receiving anthracycline or trastuzumab therapies.
Source link: https://europepmc.org/article/MED/36473307
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions